Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819047 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL15943135 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL819310 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL27382952 | 0.98 | MEN1 (0.46) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Hydrochloric Acid SCHEMBL7753577 | 0.98 | SLC2A1 (0.48) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Hydrochloric Acid SCHEMBL27389833 | 0.98 | SLC2A1 (0.48) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Oxalic Acid SCHEMBL27380050 | 0.90 | MEN1 (0.49) | MEN1KMT2AACP3ADRB2ADRB1 | |
| Fumaric Acid SCHEMBL27299351 | 0.86 | ALDH1A1 (0.50) | MEN1KMT2AACP3ADRB2ADRB1 | |
| SCHEMBL28951519 | 0.84 | ACP3 (0.46) | ACP3ADRB2ADRB1ADRB3SLC2A1 | |
| SCHEMBL9331659 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | claimed |
| CN-117659075-B | Preparation and application of imidazole derivative type column [5] arene chiral filler | 中国科学院兰州化学物理研究所 | 2025-02-11 | — | — | CN | claimed |
| WO-2024177860-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2024-08-29 | — | — | WO | claimed |
| CN-117659075-A | Preparation and application of imidazole derivative type column [5] arene chiral filler | 中国科学院兰州化学物理研究所 | 2024-03-08 | — | — | CN | claimed |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | claimed |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12559784-B2 | In chemico test for toxicity | LEBRUN LABS LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250369032-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1243580-A1 | HETEROCYCLIC IMINO COMPOUNDS AND FUNGICIDES AND INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nissan Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-0939134-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-1053990-A2 | A method of producing an aromatic ketone and an aromatic ketone composition containing it | TORAY INDUSTRIES, INC. (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | MEN1 3559/4885KMT2A 1633/4885ACP3 4619/4885 |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | MEN1 1032/4885KMT2A 2365/4885ACP3 3959/4885 |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | MEN1 3746/4885KMT2A 989/4885ACP3 4638/4885 |
| US-12559784-B2 | In chemico test for toxicity | ALPP, ALPI, CUTA | MEN1 2759/4885KMT2A 3500/4885ACP3 81/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | MEN1 4792/4885KMT2A 2090/4885ACP3 4389/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | MEN1 4098/4885KMT2A 2187/4885ACP3 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.